Jim Birchenough
Stock Analyst at Wells Fargo
(2.83)
# 1,610
Out of 5,154 analysts
29
Total ratings
52.63%
Success rate
37.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.38 | +429.80% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $56.50 | +23.89% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $24.08 | +99.34% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.33 | +9,674.44% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $3.32 | +321.69% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $52.52 | +176.09% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $143.93 | -56.23% | 5 | Oct 29, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $14.27 | +292.43% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $759.86 | -3.40% | 2 | May 26, 2020 | |
| KZR Kezar Life Sciences | Maintains: Overweight | $300 → $180 | $6.95 | +2,489.93% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $6.81 | +384.58% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.38
Upside: +429.80%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $56.50
Upside: +23.89%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $24.08
Upside: +99.34%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.33
Upside: +9,674.44%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $3.32
Upside: +321.69%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $52.52
Upside: +176.09%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $143.93
Upside: -56.23%
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $14.27
Upside: +292.43%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $759.86
Upside: -3.40%
Kezar Life Sciences
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.95
Upside: +2,489.93%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $6.81
Upside: +384.58%